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Using a proteomic approach to screen for new growth
factors released by melanoma cells, we identiﬁed follista-
tin as a major heparin-binding factor in medium condi-
tioned by the Bowes melanoma cell line. Since follistatin is
primarily studied in relation to its neutralization of
activin, a member of the transforming growth factor-b
family of ligands, the expression and function of this
receptor system was investigated in a panel of melanoma
cell lines and melanocytes. All cell lines expressed activin
receptors and showed phosphorylation of Smad signal
transduction molecules upon treatment with activin.
Secretion of follistatin, either native or after retroviral
transduction, efﬁciently prevented Smad activation or
activation of an activin-responsive luciferase reporter
construct. In melanocytes, activin treatment led to growth
inhibition and induction of apoptosis. These effects were
counteracted by cotreatment with follistatin. In summary,
we characterized the activin–activin receptor system in
melanocytes and melanoma cell lines and found that
secretion of follistatin by melanoma cells may represent
an effective way to circumvent activin’s negative regula-
tory effects.
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Introduction
Melanocytes, the pigment-forming cells of the skin, are a
quiescent cell population located in the basal layer of the
epidermis. Their growth is controlled by an interplay
with the surrounding keratinocytes (Meier et al., 1998;
La´za´r-Molna´r et al., 2000). Disturbance of this tight
control may result in an imbalance of stimulatory versus
inhibitory factors and may represent a ﬁrst step towards
malignant transformation. The transforming growth
factor-b (TGF-b) family of growth factors has been
described as an important growth-regulatory system in
melanocytes. Whereas TGF-b acts as a potent inhibitor
of growth and inducer of apoptosis in normal melano-
cytes, these effects are often much less pronounced,
absent or even inversed in melanoma cells (Rodeck et al.,
1994, 1999; Alanko and Saksela, 2000).
Activins are TGF-b-like dimeric molecules that were
initially isolated as stimulators of follicle-stimulating
hormone secretion (hence the name) (Ling et al., 1986;
Vale et al., 1986). They consist of two disulﬁde-linked b
subunits, translated from one of three known (A, B or
C) human inhibin b gene transcripts, the main activin
proteins being the homodimeric activins A and B and
the heterodimeric activin AB (Knight, 1996). They exert
their biological effects by interacting with two types of
transmembrane serine/threonine kinase receptors (types
I and II). Following binding of the dimeric ligand to two
type II receptors (II or IIB), two type I activin-like
receptor kinases (ALK4¼ activin receptor IB) are
recruited and activated by phosphorylation in trans.
On their turn, the type I receptors will phosphorylate
cytoplasmic Smad proteins (Smad2 and 3) which, after
forming a complex with Smad4, will translocate to the
nucleus to regulate transcription of activin-responsive
genes (Shi and Massague´, 2003). Activins have been
implicated in the control of diverse cellular processes,
ranging from tissue patterning during embryogenesis to
the control of homeostasis, cell growth and differentia-
tion in multiple adult tissues (Ball and Risbridger, 2001;
Luisi et al., 2001; Risbridger et al., 2001; Chen et al.,
2002; Welt et al., 2002). The effects of activin are cell-
type speciﬁc: in some tissues or cell types, it stimulates
proliferation, while in others it induces differentiation,
growth inhibition and/or apoptosis. Disruption or
deregulation of activin signaling is associated with
multiple pathological states, including inﬂammation,
reproductive disorders and carcinogenesis (Risbridger
et al., 2001; Chen et al., 2002; Cho et al., 2003). Cells
may escape from the growth inhibitory effects of activin
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in several ways: by mutation or downregulation of
activin responsive genes or inhibition of their actions or
alternatively, by alterations interfering with the activin
signal transduction pathway. The latter may occur both
by mutations or inhibitory interactions at the receptor
level as well as at the level of the Smad signal
transduction molecules (Chen et al., 2002). Alterna-
tively, several factors (inhibins, cripto, follistatin) may
interfere with the ability of activin to gain access to and/
or assemble its signaling receptors (Gumienny and
Padgett, 2002; Gray et al., 2003).
Follistatin (FS), a monomeric secreted glycoprotein
that binds activin with high afﬁnity, blocks the ability of
activin to bind its cell-surface receptors (de Winter et al.,
1996). FS was ﬁrst isolated from ovarian follicular ﬂuid
on the basis of its ability to suppress the secretion of
follicle-stimulating hormone from pituitary cells
(Robertson et al., 1987; Ueno et al., 1987), an activity
that later was found to be due to the sequestering of
activin secreted by these cells (Nakamura et al., 1990).
Up to now, almost all known biological effects of FS are
due to its high afﬁnity, nearly irreversible, binding to
activin (Nakamura et al., 1990; Schneyer et al., 1994).
Alternative splicing at the 30 end of the follistatin gene
results in two isoforms, FS-288 and FS-315, the latter
having a 27 amino-acid extension at its C-terminus
(Shimasaki et al., 1988). Both contain an N-terminal
activin-binding domain and three consecutive 10-cysteine
follistatin domains, the ﬁrst of these containing a lysine-
rich heparin-binding motif (Wang et al., 2000; Sidis et al.,
2001; Innis and Hyvo¨nen, 2003). FS-288 is primarily
bound to cell surface heparan-sulfate proteoglycans,
presumably creating a barrier that prevents activin from
accessing its receptors (Delbaere et al., 1999; Sidis et al.,
2002) and leading to endocytosis and degradation of
surface-bound activin (Hashimoto et al., 1997). FS-315
contains an additional acidic C-terminal tail which
interferes to some extent with heparin binding, rendering
this the major isoform in solution (Schneyer et al., 1996).
This feature may explain the different potencies of both
isoforms in inhibiting the actions of endogenous versus
exogenous activin. It is not fully clear what the relative
importance of the different isoforms is. Although FS-315
transcripts, in general, are more abundant than FS-288
transcripts, the biologically active form of FS-315 in vivo
may be a processed shorter form with properties similar
to those of FS-288 (Inouye et al., 1991).
Based on the identiﬁcation of FS as a newmajor heparin-
binding factor released by melanoma cells, we characterized
the activin/activin receptor system as a new growth factor
system in melanoma and melanocytes and investigated the
potential role of FS in controlling this system.
Results
Identification of follistatin as a factor secreted by
melanoma cell lines
In a screening for new growth factors secreted by
melanoma cell lines, conditioned medium (CM) from
the Bowes melanoma cell line was prepared, concen-
trated 50 times, and subjected to a triple precipitation
procedure using heparin beads in order to deplete it
from heparin-binding factors. The initial and depleted
concentrated CM and the resulting heparin-binding
fraction were subjected to gel electrophoresis, followed
by protein silver staining of the gel. This resulted in a
very similar pattern of proteins in the concentrated CM
and in the depleted concentrated CM, indicating that
the vast majority of secreted proteins did not bind to the
heparin beads (Figure 1a, lanes 1 and 2). However, a
band at 745 kDa (indicated with an asterisk) was not
present in the depleted CM. This band corresponded
with the major band found in the heparin-binding
fraction (Figure 1a, lanes 3 and 4). N-terminal sequen-
cing identiﬁed this band as FS. The sequence obtained,
GN(C)WLRQA, represents the N-terminus of mature
FS after cleavage of its precursor form (Esch et al., 1987;
Robertson et al., 1987; Ueno et al., 1987; Nakamura
et al., 1990) (Figure 1b). To ascertain that this major
band is due to FS and does not represent a major other,
N-terminally blocked protein, we performed an in-gel
digestion of this band, using trypsin. The resulting
peptides were extracted and then submitted to mass
spectrometric analysis. This conﬁrmed that the major
heparin-binding factor released by Bowes melanoma
cells was indeed FS (Figure 1b). Western blotting and
immunostaining with an anti-FS antibody conﬁrmed the
presence of FS in concentrated Bowes melanoma CM,
but not in concentrated CM depleted of heparin-binding
factors (Figure 1c). To verify whether the different
molecular weight forms recognized by the antibody
represent different FS isoforms or result from differ-
ential post-translational modiﬁcations (glycosylation, C-
terminal processing), the Bowes melanoma cell line was
treated for 24 h with the glycosylation inhibitor tunica-
mycin before harvesting the CM. Subsequent immunos-
taining of this concentrated CM with an anti-FS
antibody revealed only one, faster migrating band
(Figure 1d), meaning that the different bands seen in
CM from the Bowes melanoma cell line represent
differentially glycosylated forms of one FS isoform. As
the tryptic peptides that had been identiﬁed by mass
spectrometry did not allow us to conclude which
isoform (FS-288 or FS-315) was produced by these
cells, we focused further on the tryptic fragment that
would be obtained from the C-terminus. However,
although we screened speciﬁcally for masses of potential
C-terminal peptides by mass spectrometry, we could not
identify this peptide. This may be due to the highly
hydrophilic nature of the C-terminus or, alternatively,
may mean that the C-terminus of mature FS is close to
the last trypsin cleavage site, and would thus give rise to
a peptide that is too small to be detected.
As an alternative approach to identify which FS
isoform was produced, RT–polymerase chain reaction
(PCR) was performed. A primer set was designed such
that different lengths of ampliﬁcation products were
obtained, depending on the isoform present. This primer
set was used to amplify cDNA from Bowes melanoma
cells, melanocytes and melanocytes that had been
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cultured in the presence of the phorbolester PMA, a
known upregulator of FS (Tano et al., 1995). As
compared to nonstimulated melanocytes, high FS-315
mRNA levels were found in Bowes melanoma cells and
in melanocytes cultured in the presence of PMA. In all
cases, only an ampliﬁcation product derived from the
FS-315-encoding mRNA was obtained (Figure 1e). This
isoform has been described to be the major FS isoform
in solution (in contrast to FS-288, which is primarily cell
surface bound), consistent with our isolation of FS as a
factor secreted in the medium.
To verify whether FS production was also seen in
other melanoma cell lines, we analysed concentrated
CM from a panel of melanoma cell lines by Western
blotting (Figure 1f). This revealed that, albeit lower than
was found for the Bowes melanoma cell line, FS
secretion was easily detectable in several cell lines (530,
A375, DX3), whereas lower (FM45, FM87, HMB2) to
faint signals were obtained in others (e.g. FM3/P,
MeWo). None of the cell lines accumulated higher FS
levels than those found for the Bowes melanoma cell
line. Also here, RT–PCR analysis learned that FS-315
was the only isoform produced by melanoma cells (data
not shown). In conclusion, several melanoma cell lines
release FS-315, either as a full-length or a C-terminal-
truncated form, in their medium.
Expression of activin and activin receptors in melanoma
cell lines
Since nearly all known effects of FS are mediated via its
binding to and neutralization of activin, we ﬁrst
characterized whether activin can act on melanoma
cells. Therefore, we performed RT–PCR for activin
receptors I, IB, II and IIB. Of these, activin receptors IB
and IIB were highly expressed in all melanoma cell lines
and melanocytes (Figure 2). To verify whether activin
and inhibin were produced by melanocytes and the
melanoma cells, we performed RT–PCR for the inhibin
a-subunit and the bA, bB and bC subunits (Figure 2).
This revealed a high expression of the bA subunit in the
majority of the melanoma cell lines, suggesting that
activin A, a homodimer of two bA subunits, is the major
activin expressed in this type of cells. Melanocytes
cultured in the presence of PMA had higher mRNA
levels of inhibin-a, -bA and -bB, consistent with the
PMA-induced upregulation of activin expression and
secretion in a variety of cells (Cho et al., 2003). To
quantify activin A secretion by the melanoma cells, we
set up an ELISA, which allowed us to detect activin A
levels as low as 0.25 ng/100 ml. When 25-fold concen-
trated CM of the melanoma cell lines was tested in this
ELISA, no speciﬁc signal could be obtained, meaning
that activin A levels in the melanoma cell lines do not
exceed 0.1 ng/ml (data not shown). Using a similar
ELISA to detect FS, a signal was easily obtained using
crude CM from the Bowes melanoma and FS-trans-
duced FM3/P cell lines, whereas vector-transduced
FM3/P cells were completely negative (data not shown).
These data suggest that activin A is secreted in only very
low amounts by the melanoma cells, or may remain cell-
surface associated, leading to residual levels in the
medium, or may, in contrast to FS, be subject to fast
proteolytical breakdown.
Figure 1 Follistatin secretion by melanoma cell lines. (a) Protein silver staining and (c) immunoblotting (I.B.) with an anti-FS
antibody of 50 concentrated CM of Bowes melanoma cells (lane 1), CM depleted from heparin-binding factors (lane 2), the heparin-
binding fraction of the CM (lane 3) or a more concentrated heparin-binding fraction (lane 4). (b) Sequence of FS precursor with the
sequences identiﬁed by mass spectrometry (underlined). 4 Indicates the N-terminus of mature FS that was identiﬁed by N-terminal
sequencing. 1 Indicates the C-terminus of FS-288. (d) Immunoblotting with anti-FS antibody of 50 concentrated CM of Bowes
melanoma cells, left untreated (U) or treated for 24 h with 10 mg/ml tunicamycin (Tun). (e) RT–PCR analysis of FS mRNA in the
indicated cells. (f) Immunoblotting with anti-FS antibody of 50 concentrated CM of the indicated cell lines. The asterisk indicates
the band(s) corresponding to FS
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Activin-induced Smad-phosphorylation in melanoma cell
lines
Receptor activation by members of the TGF-b family of
growth factors is typically followed by activation
(phosphorylation) of receptor Smads (Shi and Massa-
gue´, 2003). Using a phospho-Smad-speciﬁc antibody, we
determined whether the addition of activin indeed
resulted in activation of Smads in the cells. We therefore
added activin to serum-free medium or to medium
conditioned for 48 h by the melanoma cell lines. Positive
and negative controls, respectively, were the human
breast cancer cell line MCF-7 (Liu et al., 1996) and the
human colon cancer cell line HCT-8, the latter having a
nonsense mutation in activin receptor II (Hempen et al.,
2003) (Figure 3, upper panel). Note that basal Smad
activation levels seen in Figure 3 should not be
compared between cell lines, since differences in band
intensities between blots may be the result of different
ﬁlm exposure times. When activin was added in fresh
serum-free medium, Smad phosphorylation increased in
all melanoma cell lines tested, meaning that the ﬁrst
steps of the activin signal transduction (receptor binding
and activation of signal transduction molecules) re-
mained intact (Figure 3, middle panel, last two lanes).
Of note, the Smad activation observed was much more
pronounced than that seen in treated MCF-7 breast
cancer cells, possibly due to the higher receptor levels in
all of the melanoma cell lines (Figure 2). Smad
phosphorylation following activin treatment in fresh,
serum-containing medium was also seen in melanocytes
(Figure 3, lower panel, last two lanes). Here, serum
starvation was omitted, since the majority of melano-
cytes does not survive, or goes into apoptosis, after a
48-h serum depletion (unpublished observations). To
verify whether the presence of secreted factors inﬂuences
the response of the cells, activin was added to medium
conditioned by the cells. In several melanoma cell lines,
this resulted in a lower (e.g. A375, DX3) or even
completely absent (Bowes) Smad activation, when
compared to activin treatment in fresh medium
(Figure 3, ﬁrst two lanes). This means that, although
these cell lines have retained the intrinsic capacity to
respond to activin in terms of Smad activation, the
secretion of (an) inhibitory factor(s) prevents this
activation. Since the prevention of Smad activation
following activin treatment in the CM correlated well
with the presence of FS in this CM (Figure 1f), the
action of FS, secreted by melanoma cells, was further
investigated.
Follistatin-315 secretion by melanoma cell lines inhibits
activin-induced Smad activation
In the Bowes melanoma cell line, secreting the highest
amounts of FS (Figure 1f), Smad phosphorylation was
not altered upon addition of activin to the CM (Figure 3
and 4a). We therefore chose this cell line to provide
further evidence that activin’s stimulatory effects are
indeed blocked by secretion of FS into the medium.
Bowes melanoma cells were ﬁrst washed extensively
before the addition of activin to CM or to fresh medium.
When administered in the CM, activin treatment did not
lead to an increase in Smad phosphorylation, irrespec-
tive of whether (Figure 4a, lanes 3 and 4) or not (lanes 1
and 2) the cells had been washed before the treatment.
Addition of activin to serum-free medium that was
added to washed cells did result in increased Smad
Figure 3 Activin treatment of melanoma cells and melanocytes
induces Smad activation. Immunoblotting (I.B.), using an anti-
phospho-Smad antibody of whole-cell lysates of the indicated cells.
All cell lines were serum starved for 48 h before a 30-min treatment
with activin (10 ng/ml) in their medium (CM) or in fresh serum-free
medium that was added to cells that had been washed three times
with PBS (Fresh Med). In the case of melanocytes, CM and Fresh
Med indicate serum-containing medium
Figure 2 Expression of the activin–activin receptor system in
melanoma cell lines and melanocytes. RT–PCR analysis of activin
receptors and activin/inhibin subunits in the indicated cell lines. b2-
microglobulin (b2-MG) was used as a control
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activation (lanes 7 and 8). Taken together, this shows
that Bowes melanoma cells release a factor in their
medium that prevents activin-induced Smad activation.
Since FS is a heparin-binding factor, we next depleted
Bowes melanoma CM from heparin-binding factors
(CMdep). Interestingly, treatment with CMdep already
leads to an increase in Smad activation (Figure 4a,
lane5), and addition of activin to this medium does not
result in an increase in Smad phosphorylation
(Figure 4a, lane 6). This raises the possibility that, by
depleting Bowes melanoma CM from FS, the balance
between endogenous activin and FS is disrupted, readily
leading to Smad activation. Finally, to provide proof
that the production and secretion of the FS-315 isoform
by melanoma cell lines can indeed fully prevent Smad
activation by activin, two FS-negative cell lines, FM3/P
and MeWo, were infected with the retroviral vector
pLZRS-FS315-internal ribosomal entry site (IRES)-
enhanced green ﬂuorescent protein (EGFP). An IRES
allows both FS315 and EGFP to be translated
separately from the same mRNA transcript, with
expression levels of FS315 and EGFP being directly
proportional. As a control, retroviral transduction with
pLZRS-IRES-EGFP, encoding only EGFP, was per-
formed. As shown in Figure 4b, transduction with
retrovirus containing either an empty vector (pLZRS-
IRES-EGFP, LIE) or FS (pLZRS-FS315-IRES-EGFP,
FS) resulted in an efﬁciency of around 50% for both
melanoma cell lines. As evidenced by Western blotting,
FS-transduced, but not empty-vector-transduced cells,
secreted FS into their medium (Figure 4c). Owing to this
secretion, we reasoned that further sorting of these
cell lines would not be necessary to investigate its
effects: FS produced by the transduced cell lines was
likely to protect nontransduced cells as well. No
differences in morphology or growth could be observed
between the two transduced populations, either in the
presence or absence of activin (data not shown). When
tested for Smad activation, both the empty-vector- and
FS-transduced FM3/P and MeWo cell lines were
responsive to activin, when added in serum-free medium
(Figure 4d, lanes 5 and 6). However, similar to what was
observed in the Bowes melanoma cell line, no increase
in Smad activation occurred when activin was added
immediately to FS-transduced cells (lanes 1 and 2) or,
alternatively, was added to 48-h conditioned medium
that was added to washed cells (lanes 3 and 4). T
his contrasts with the empty-vector-transduced cells,
which were still fully responsive to activin (lanes 1, 2
and 3, 4). In agreement with this, treatment of
washed Bowes melanoma cells with activin in CM from
FM3/P FS did not lead to increased Smad activation
(Figure 4e, lanes 5 and 6), in contrast to its addition in
fresh serum-free medium or in CM from FM3/P LIE
(lanes 1, 2 and 3, 4). In conclusion, FS secretion by
melanoma cells is an effective way to prevent Smad
activation by activin.
Follistatin secretion by melanoma cell lines inhibits their
response to an activin-responsive reporter gene construct
Since the activation of receptor-Smads does not
necessarily mean that the signal will lead to alterations
in gene transcription, we performed luciferase-reporter
assays using the TGF-b- and activin-responsive CAGA
promoter construct (Dennler et al., 1998). Activin
treatment of FM3/P cells resulted in a twofold increase
Figure 4 Follistatin secretion prevents activin-mediated Smad
activation. (a) Immunoblotting (I.B.), using an anti-phospho-Smad
antibody of total lysates of Bowes melanoma cells. The 48-h serum-
starved cells were washed three times with PBS (washed), or were
not, and treated with activin (10 ng/ml) for 30min in their CM
(CM), in this CM depleted from heparin-binding factors (CMdep)
or in fresh serum-free medium (Fresh Med). (b) Dot plot analysis of
EGFP expression by the indicated retrovirally transduced cell lines.
Percent positivity is indicated in the upper right panel. (c)
Immunoblotting, using an anti-FS antibody, of 50 concentrated
CM of the indicated retrovirally transduced cell lines. The asterisk
indicates the band corresponding to FS. (d) and (e) Immunoblot-
ting (I.B.), using an anti-phospho-Smad antibody of total lysates of
the indicated cell lines. The 48-h serum-starved cells were washed
three times with PBS (washed), or were not, and treated with
activin (10 ng/ml) for 30min in their CM (CM) or in fresh serum-
free medium (Fresh Med). LIE indicates cells transduced with
empty vector, FS indicates cells transduced with FS-315. In (e), also
non-self serum-free CM was used
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of luciferase activity that could be completely inhibited
by the addition of exogenous FS (Figure 5a). When the
transduced cells were tested, a similar increase was seen
in empty-vector-transduced cells, whereas the FS-
transduced FM3/P cells did not show any increase in
promoter activity (Figure 5b). This conﬁrms the results
of Smad activation and, again, shows that the secretion
of FS by melanoma cells is an effective mechanism to
neutralize the effects of activin.
Activin inhibits melanocyte growth and induces apoptosis
Since TGF-b has been described as a proapoptotic
and growth-inhibitory factor for melanocytes, we
addressed the question whether activin may have
similar effects. Melanocytes cultured in the presence of
activin showed a marked decrease in growth, as
measured by mitochondrial activity using the MTT
assay (Figure 6a). This decrease could be counteracted
in a dose-dependent way by cotreatment with FS,
which, when administered alone, did not have an effect
on the growth of melanocytes. To verify whether an
increase in apoptosis can provide an explanation for the
observed decrease in growth, we performed Annexin V
labeling of serum-starved melanocytes that were treated
or not with activin. Annexin V has a high afﬁnity for
phosphatidylserine, which is exposed at the outer
surface of the cells in early apoptosis. Deprivation of
melanocytes from growth factors readily renders them
susceptible to apoptosis. As is evident from Figure 6b, a
20-h treatment with activin results in a signiﬁcant
increase in apoptosis, thus providing a likely explana-
tion for the decreased ‘growth’ observed, as measured
by mitochondrial activity. Again, this effect could
be counteracted by coadministering FS. In conclusion,
FS protects melanocytes against growth inhibition
by activin, at least partly, by counteracting its proa-
poptotic effects.
Discussion
Although TGF-b-like molecules have been studied
for more than a decade in melanocytes and their
malignant derivatives, surprisingly, only the roles of
TGF-b itself have been looked at (Rodeck et al., 1994,
1999; Alanko and Saksela, 2000). In the present paper,
based on the identiﬁcation of FS as a major heparin-
binding growth factor released by melanoma cells, we
studied the activin/FS system as a new regulatory
growth factor system in melanocytes and melanoma
cell lines.
Melanocytes are neural crest-derived cells that mi-
grate to the skin during an early stage of development.
They form a quiescent population in the basal layer of
the epidermis, making extensive contacts with the
surrounding keratinocytes, to which they deliver mela-
nin. Conversely, keratinocytes are crucial in controlling
normal proliferation of melanocytes. They do so in a
contact-dependent manner by the formation of E-
cadherin-mediated adherens junctions with the melano-
cytes, necessary for and leading to the formation of gap
junctions (Meier et al., 1998). A delicate balance exists
between stimulatory and inhibitory factors, released
either by the melanocytes themselves or by the
keratinocytes. Loss of control of keratinocytes over
melanocytes may thus be the result of altered cell–cell
adhesion and/or alterations in growth factor systems in
either of both partners. A shift in the balance between
positive (basic ﬁbroblast growth factor, insulin-like
growth factor-I, heregulin, etc.) and negative (TGF-b,
interleukin-6, etc.) regulators of melanocyte growth may
represent a ﬁrst step towards uncontrolled proliferation
(La´za´r-Molna´r et al., 2000; Stove et al., 2003a). Here, we
have shown that activin may serve as a novel negative
regulatory factor controlling melanocyte proliferation.
Exogenous activin is able to inhibit proliferation and
induce apoptosis in primary melanocytes. These effects
resemble those of TGF-b (Alanko and Saksela, 2000). In
vivo, activin may be provided by the keratinocytes,
Figure 6 Follistatin counteracts activin-mediated growth inhibi-
tion and apoptosis in melanocytes. (a) Growth, relative to
untreated cells, as measured by MTT assay. Melanocytes were
treated for 4 days with activin (25 ng/ml) and the indicated
concentration of follistatin. (b) % Annexin V positivity of serum-
starved melanocytes that have been treated for 20 h with activin
(25 ng/ml) and/or follistatin (400 ng/ml). Asterisks indicate means
that differ signiﬁcantly (Po0.05) from control
Figure 5 Follistatin prevents activin-mediated induction of a
luciferase reporter construct. Activin (25 ng/ml) and/or follistatin
(100 ng/ml) was added for 30min to the indicated melanoma cell
lines that had been transiently transfected with a b-galactosidase
reporter construct and a luciferase-reporter construct with an
activin-responsive promoter (open bars), without a promoter
(black bars) or with a constitutively active promoter (gray bars).
Bars represent normalized luciferase activities, relative to untreated
cells. In (a), a representative experiment is shown, in (b), the
asterisk indicates that the mean is signiﬁcantly larger than the
control (Po0.05)
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which are known producers of this molecule (Beer et al.,
2000). Using transgenic mice, a role for keratinocyte-
derived activin in the skin has been shown to exist in
wound healing processes and in the regulation of cell
matrix deposition (Munz et al., 1999; Wankell et al.,
2001b). Although, in vitro, keratinocyte proliferation
was shown to be decreased by activin, no decreased
keratinocyte proliferation was observed in vivo, possibly
because of the induction by activin of other factors that
may act as prosurvival factors for the keratinocytes
(Beer et al., 2000). Here, we found that both melano-
cytes and melanoma cells express mRNA for inhibin b
subunits, primarily the bA subunit, presumably leading
to the formation of the homodimeric activin A.
Expression of this bA subunit was markedly higher in
melanocytes cultured in PMA-containing medium,
consistent with the fact that PMA is a known inducer
of activin (Cho et al., 2003). However, surprisingly,
measurement of activin A levels in melanoma CM
revealed that activin A levels in none of the melanoma
cell lines exceeded 0.1 ng/ml. Although it is possible that
melanoma cells indeed secrete only residual amounts of
activin A, we cannot exclude that it is rapidly degraded,
or alternatively, remains associated with the cell surface,
prohibiting measurement in the CM. Therefore,
although several of the melanoma cell lines had higher
expression of the bA subunit, when compared to the
levels found in non-PMA treated melanocytes, a role for
activin in melanomagenesis, as has been proposed for
TGF-b (Shellman et al., 2000; Berking et al., 2001),
remains speculative. Further in vitro and in vivo
experiments, using activin-transduced cells, are needed
to clarify this issue.
Early in malignant transformation, it is crucial for the
survival of transformed cells to proﬁt optimally from
mitogenic stimuli, while escaping from inhibitory
signals. Overexpression or mutation of receptor systems,
or the gain of autocrine loops, may contribute to the
ﬁrst, while downregulation of inhibitory receptors or the
secretion of ligand traps have been shown to contribute
to the latter (Massague´ and Chen, 2000; Blume-Jensen
and Hunter, 2001; Gullick, 2001). Since activin acts as
an inhibitory molecule for melanocytes, neutralization
of its effects implies the release from a negative
regulatory factor. As shown here, one way to do so is
the production and secretion of FS. By binding to
activin, FS sequesters it in the medium and prevents it
from accessing its cell surface receptors. As a result,
although these cell lines have an intact signaling
machinery, no signaling occurs when activin is added
to medium in which these cells have released FS
previously. A similar activin-inhibitory effect has been
described for the more recently described follistatin-
related protein FLRG/FSTL3 (Sidis et al., 2002). Using
RT–PCR, we found transcripts of the latter in
melanocytes and in all melanoma cells (data not shown).
However, we consider it unlikely that follistatin-related
protein would play a major role in our system, since (1)
no correlation could be found between its expression
and the activin responsiveness of the cells, with FLRG/
FSTL3-expressing cells still being fully responsive when
activin was administered in their CM and (2) FLRG/
FSTL3 lacks a heparin-binding site, while the activin-
neutralizing effect of our CM can be abolished by
depleting it from heparin-binding factors. FS is a known
target gene of the canonical Wnt signaling pathway, in
which b-catenin translocation to the nucleus results in
transcriptional activation of target genes (Willert et al.,
2002). In cancer, including melanoma, b-catenin muta-
tions may lead to constitutive activation of this path-
way, resulting in aberrant activation of these target
genes (Rubinfeld et al., 1997). However, examination of
b-catenin localization in our panel of melanoma cell
lines did not reveal obvious nuclear b-catenin localiza-
tion in any cell line (data not shown). Other factors
capable of regulating FS secretion include retinoic acid,
prostaglandin E2, activators of protein kinase A and C,
as well as growth factors such as keratinocyte growth
factor and epidermal growth factor (Michel and Farn-
worth, 1992; Wankell et al., 2001a). Interesting in this
respect is our recent identiﬁcation of a potent autocrine
loop of heregulin, an epidermal growth factor-like
ligand, in the Bowes melanoma cell line, which secretes
the highest amounts of FS (Stove et al., 2003a). Whether
there is a crosstalk between receptor tyrosine kinase
pathways and regulation of FS expression in melanoma
cell lines is currently being investigated. We could not
ﬁnd a clear correlation between FS expression and the
differentiation status of the cell lines in our panel: FS
secretion was both present in cell lines that had lost
several melanocytic markers (e.g. Bowes melanoma,
A375 and DX3) as in cell lines that retained, at least
partly, markers of differentiation (e.g. the pigmented
530 and FM87).
Surprisingly, although the ﬁrst steps in the activin
signaling pathway were intact in all cell lines tested,
none of the melanoma cell lines showed signiﬁcant
growth inhibition following activin treatment, in con-
trast to what was seen for melanocytes. Several
explanations may account for this. Important for
activin’s growth-inhibitory effects is the modulation of
genes involved in cell-cycle regulation (Chen et al.,
2002). These genes are frequently mutated in melanoma
(Bartkova et al., 1996). Alternatively, activation of the
MAPK pathway, either by mutation of signaling
molecules (N-ras and B-raf) (Davies et al., 2002;
Tuveson et al., 2003) or by autocrine loops (La´za´r-
Molna´r et al., 2000; Stove et al., 2003a) was shown to be
of major importance in many melanomas. Constitutive
activation of this pathway was shown to result in
insensitivity to growth inhibition by TGF-b, while still
allowing other effects of these molecules to occur
(Shellman et al., 2000).
In conclusion, the effects of the activin–follistatin
system in melanoma may be dual: while early in
progression the secretion of FS may be crucial as a
protection against activin’s inhibitory effects, cells in a
later stage may use activin – either autocrine or
paracrine – to maintain a state of dedifferentiation and
to create a supportive microenvironment. It will be
important to determine the presence of this growth
factor system in tumor samples from melanoma patients
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in different stages of progression, in order to evaluate
whether it may become a therapeutic target.
Materials and methods
Cell lines
The cell lines were obtained and cultured as described before
(Stove et al., 2003a). Epidermal melanocyte primary cultures
were obtained from neonatal foreskins and established in
M199 medium (Gibco BRL, Merelbeke, Belgium), supplemen-
ted with 2% fetal bovine serum, 109 M cholera toxin, 10 ng/ml
basic ﬁbroblast growth factor, 10 mg/ml insulin, 1.4mM
hydrocortisone and 10 mg/ml transferrin (all from Sigma,
Bornem, Belgium). Postprimary cultures were maintained in
low-calcium (0.03mM) M199 medium, supplemented with the
same factors and 10% fetal bovine serum. The melanocytic
origin of all melanoma cell lines was checked by immunocy-
tochemistry using two melanoma-speciﬁc antibodies, HMB45
(Enzo Diagnostics, Farmingdale, NY, USA) and NKI/C3
(Biogenex, San Ramon, CA, USA). All melanoma cell lines
were positive for at least one of these markers (data not
shown). As most of the experiments were carried out with
Bowes melanoma cells, which were only positive for NKI/C3,
additional electron microscopy was performed to conﬁrm the
presence of premelanosome-like structures in this nonpigmen-
ted cell line (data not shown).
Antibodies and reagents
Primary antibodies used were mouse monoclonal anti-follista-
tin (R&D Systems, Abingdon, UK) and rabbit polyclonal
anti-phospho-Smad 2 (Cell Signaling Technology, Beverly,
MA, USA). Recombinant activin and follistatin were pur-
chased from R&D Systems, tunicamycin was obtained from
Sigma.
Preparation of CM
Subconﬂuent monolayers were washed three times with
phosphate-buffered saline (PBS), incubated for 24 h with
serum-free medium, washed again three times with PBS,
followed by a 48 h incubation with serum-free medium. The
latter was cleared from cells by a 5-min centrifugation step at
250 g. The resulting supernatant was centrifuged for an
additional 20min at 2000 g to remove cell debris, ﬁltered
through a 0.2mm ﬁlter, and stored at 201C until use. To
isolate the heparin-binding fraction from the CM, the latter
was depleted from heparin-binding factors by triple precipita-
tions with heparin beads (Bio-Rad, Hercules, CA, USA).
Elution of the heparin-binding fraction was carried out with
1M NaCl, followed by desalting using Microcon ﬁlters.
Western blotting
All lysates were made from cell cultures of approximately 90%
conﬂuence. For phosphorylation experiments, cells were
washed three times with PBS and serum starved for 48 h.
Then, the cells were treated without washing or, alternatively,
after washing three times with PBS. Immediately after the
treatments, the cells were washed three times with PBS before
lysis with PBS containing 1% Triton X-100, 1% Nonidet P-40
(Sigma) and the following protease inhibitors: aprotinin
(10mg/ml), leupeptin (10 mg/ml) (ICN Biomedicals, Costa
Mesa, CA, USA), phenylmethylsulfonyl ﬂuoride (1.72mM),
NaF (100mM), NaVO3 (500 mM) and Na4P2O7 (500mg/ml)
(Sigma). After clearing the lysates, protein concentration was
determined using the Rc Dc Protein Assay (Bio-Rad), and
samples were prepared such that equal amounts of protein
were to be loaded. Sample buffer (Laemmli) with 5% 2-
mercaptoethanol and 0.012% bromophenol blue was added,
followed by boiling for 5min and separation of the proteins by
gel electrophoresis on 8 or 12% polyacrylamide gels and
transfer onto a nitrocellulose membrane (Amersham Pharma-
cia Biotech, UK). Quenching and immunostaining of the blots
was performed in 5% nonfat dry milk in PBS containing 0.5%
Tween-20. The membranes were quenched for 30min,
incubated with primary antibody for 2 h, washed four times
for 5min, incubated with horseradish peroxidase-conjugated
secondary antibody for 30min, and washed ﬁve times for
5min. Detection was carried out using enhanced chemilumi-
nescence reagent (Amersham Pharmacia Biotech) as a
substrate. To control for equal loading of total lysates,
immunostaining with anti-tubulin antibody was performed
routinely (not shown).
N-terminal sequencing and mass spectrometry
N-terminal sequence analysis of a PVDF electroblotted sample
was performed on a 476A Protein sequencer. For mass
spectrometric analysis, the gel slice containing the band of
interest was excised and washed twice with 200mM ammonium
bicarbonate in 50% acetonitrile/water (20min, at 301C),
and allowed to dry at room temperature. The tube was then
chilled on ice and 8ml of digestion buffer (50mM ammonium
bicarbonate, pH 7.8) containing 150 ng of modiﬁed trypsin
was added. The sample was kept on ice for 45min, after
which 15 ml of digestion buffer was added, followed by
overnight incubation at 371C. The supernatant was recovered,
and the peptides were extracted from the gel piece by
washing twice with 60% acetonitrile/0.1% formic acid in
water. The extracts were then combined, followed by drying
in a Speedvac centrifuge. The sample was dissolved in
0.1% formic acid and injected in an automated nano-HPLC
system (Dionex) (Devreese et al., 2002). The separated
peptides were detected on-line by an ESI-Q-TRAP mass
spectrometer (Applied Biosystems/MDS Sciex, Concord, ON,
Canada) (Hager, 2002), equipped with a nanospray ion
source (Protana, Odense, Denmark). In this method, an
automated MS to MS/MS switching protocol was used for
LC-MS/MS analysis of the peptides (Sandra et al., 2004).
Brieﬂy, ﬁrst an enhanced MS scan as survey scan (m/z
400–1500), followed by an enhanced resolution scan of the two
most intense ions was performed. If their charge state was þ 2
or þ 3, an enhanced product ion scan (MS/MS) of these ions
was performed. The total cycle time of this set-up was
approximately 4.5 s.
RT–PCR
Total RNA was extracted from approximately 5 106 cells
using the Qiagen RNEASY kit (Qiagen, Chatsworth, CA,
USA). In total, 1 mg of total RNA was reverse-transcribed with
oligo-dT primers using the Qiagen RT kit (Qiagen) according
to the manufacturer’s instructions. PCR was performed on
250 ng template cDNA using the Qiagen Taq PCR kit (Qiagen)
according to the manufacturer’s instructions. Reactions were
carried out in a Minicycler (Biozym, The Netherlands) with an
initial denaturation at 941C for 3min, 35 cycles of 941C for 50 s
(denaturation), 611C for 50 s (annealing), and 721C for 1min
(elongation), followed by a ﬁnal extension at 721C for 10min.
Table 1 lists the primers that were used.
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Retroviral transduction
FS315 was Tsp509I digested from the FS315 plasmid
construct, pSV2HF-315 (Inouye et al., 1991), and EcoRI
subcloned into the retroviral vector LZRS-IRES-EGFP. This
control vector expresses only EGFP from an IRES. The
production of retroviral supernatant was carried out as
described before (Stove et al., 2003b). Brieﬂy, the Phoenix-
Amphotropic packaging cell line (a kind gift from Dr GP
Nolan, Stanford University School of Medicine, Stanford, CA,
USA) was transfected with the LZRS-IRES-EGFP control
vector, or with LZRS-FS315-IRES-EGFP, by using calcium-
phosphate precipitation (Invitrogen, San Diego, CA, USA) to
generate the retrovirus. The retroviral supernatant was spun
(10min for 350 g) and aliquots were stored at 701C until use.
For transduction of cell lines, cells were mixed with retroviral
supernatant that was incubated for 10min with Dotap (Roche
Molecular Biochemicals, Mannheim, Germany). To increase
transduction efﬁciency, cells were spun (90min, 950 g, 321C).
Transduction efﬁciency was evaluated by ﬂow cytometry.
Cell proliferation assay
A total of 12 500 melanocytes were seeded into the wells of a 96-
well plate in 100ml DMEM medium containing 10% fetal
bovine serum. After 24 h, the cells were washed twice with
serum-free DMEM and then treated with 200ml serum-free
medium, supplemented with growth factors as indicated. After 4
days, metabolic activity was measured with a colorimetric assay,
using 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) (Sigma), as described before (Stove et al., 2003a).
Annexin V staining
150 000 melanocytes were seeded in the wells of a 24-well plate
in 1ml DMEM medium containing 10% fetal bovine serum.
After 24 h, the cells were washed twice with serum-free DMEM
and then treated for 20 h with 500ml serum-free medium,
supplemented with growth factors as indicated. After detach-
ing the cells, Annexin V staining and ﬂow cytometric analysis
were performed as described before (Stove et al., 2003a).
Luciferase reporter assay
A total of 100 000 cells were seeded per well of a 24-well plate.
After 24 h, cells were transfected with 300 ng of pGL3basic,
pGL3 control (Promega) or the CAGA luciferase reporter
construct (Dennler et al., 1998), together with 100 ng pUT
b-galactosidase reporter construct to normalize for transfec-
tion efﬁciencies. Some 24 h after transfection, cells were
treated, or left untreated, for 20 h, after which they were lysed.
After freezing the lysates for 1 h at 801C and thawing, they
were cleared from debris by centrifugation and used for
measuring luciferase- and b-galactosidase activities.
Statistics
Differences between means were considered as signiﬁcant
when the P-value was o0.05, using Student’s t-test.
Abbreviations
CM, conditioned medium; EGFP, enhanced green ﬂuores-
cence protein; FS, follistatin; IRES, internal ribosomal entry
site; LIE, LZRS-IRES-EGFP; PMA, phorbol 12-myristate 13-
acetate; TGF-b, transforming growth factor-b.
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